Afami-Cel Yields Durable Responses in Heavily Pretreated Synovial Sarcoma

Afamitresgene autoleucel (afami-cel), a T-cell therapy, showed promising results in treating synovial sarcoma in a phase 2 trial. The therapy led to durable responses in heavily pretreated patients, with an overall response rate of 37%. The median time to response was 4.9 weeks, and the median duration of response was 11.6 months in patients with synovial sarcoma. Common adverse events included cytopenias and cytokine release syndrome, but there were no treatment-related deaths. The therapy is currently under review for FDA approval and could potentially offer a new treatment option for synovial sarcoma patients.

Source link

error: Content is protected !!